A case of six year survival with combined immunotherapy and antiangiogenesis for refractory ccRCC with brain metastasis
This case report demonstrates that a combination of immune checkpoint inhibitors and bevacizumab can achieve long-term disease control and a six-year overall survival in a patient with refractory clear cell renal cell carcinoma and brain metastasis who had previously failed multiple lines of tyrosine kinase inhibitor therapy.